1. MCL‐R2 ELDERLY: A PHASE III STUDY OF THE EUROPEAN MCL NETWORK ASSESSING EFFICACY OF ALTERNATING IMMUNOCHEMOTHERAPY (R‐CHOP / R‐HAD) AND a RITUXIMAB‐LENALIDOMIDE MAINTENANCE. (June 2017) Authors: Ribrag, V.; Feugier, P.; Doorduijn, J.; Delfau‐Larue, M.; Hermine, O.; Kluin‐Nelemans, H.; Dasilva, M.; Lopez‐Hernandez, A.; Walewski, J.; Szymczyk, M.; Pott, C.; Homburg, C.; Van der Velden, V.; Gameiro, P.; Garcia‐Sanz, R.; Ladetto, M.; van Krieken, H.; Cabeçadas, J.; Rymkiewicz, G.; Klapper, W. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 421 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. MOLECULAR ANALYSES AND AN INNOVATIVE DIAGNOSTIC ALGORITHM IN MYC‐NEGATIVE BURKITT‐LIKE LYMPHOMA WITH 11Q ABERRATION: A SINGLE INSTITUTION EXPERIENCE. (12th June 2019) Authors: Rymkiewicz, G.; Zajdel, M.; Paziewska, A.; Blachnio, K.; Grygalewicz, B.; Woroniecka, R.; Dabrowska, M.; Bystydzienski, Z.; Romejko‐Jarosinska, J.; Kulecka, M.; Kulinczak, M.; Sromek, M.; Rygier, J.; Borysiuk, A.; Pienkowska‐Grela, B.; Czyz‐Domanska, K.; Miloszewska, J.; Szafron, L.; Prochorec‐So... Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 190 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OFATUMUMAB WITH IVAC FOR DLBCL PATIENTS WHO FAILED R‐CHOP AND WERE NOT CANDIDATES FOR HIGH‐DOSE THERAPY AND ASCT ‐ PHASE 2 TRIAL OF THE POLISH LYMPHOMA RESEARCH GROUP (PLRG‐8). (12th June 2019) Authors: Paszkiewicz‐Kozik, E.; Michalski, W.; Taszner, M.; Knopińska‐Posłuszny, W.; Mordak‐Domagała, M.; Najda, J.; Borawska, A.; Romejko‐Jarosińska, J.; Chełstowska, M.; Świerkowska, M.; Dąbrowska‐Iwanicka, A.; Malenda, A.; Druzd‐Sitek, A.; Konecki, R.; Kuniega, B.; Osowiecki, M.; Ostrowska, B.; Szpila,... Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 436 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P53 BUT NOT SOX11 IHC HAS PROGNOSTIC VALUE INDEPENDENT OF MIPI AND KI‐67 IN PROSPECTIVE TRIALS OF THE EUROPEAN‐MCL NETWORK. (June 2017) Authors: Aukema, S.M.; Hoster, E.; Rosenwald, A.; Canoni, D.; Rymkiewicz, G.; Thorns, C.; Hartmann, S.; Kluin‐Nelemans, H.C.; Hermine, O.; Dreyling, M.; Klapper, W. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. R‐ DAEPOCH as a first line treatment for high grade B cell lymphoma and diffuse large B cell lymphoma with unfavorable features. (June 2017) Authors: Romejko‐Jarosinska, J.; Rymkiewicz, G.; Paszkiewicz‐Kozik, E.; Dabrowska‐Iwanicka, A.P.; Borawska, A.; Domanska‐Czyz, K.; Konecki, R.; Kotarska, M.; Osowiecki, M.; Ostrowska, B.; Poplawska, L.; Swierkowska‐Czeneszew, M.; Szymanski, M.; Targonski, Ł.; Blachnio, K.; Bystydzienski, Z.; Grygalewicz, ... Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 335 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. R‐CHOP is not effective regimen in CD5(+)DLBCL diagnosed by flow‐cytometry/immunohistochemistry, karyotype and BCL2/BCL6 status and expression. (June 2017) Authors: Rymkiewicz, G.; Romejko‐Jarosinska, J.; Paszkiewicz‐Kozik, E.; Błachnio, K.; Kotarska, M.; Bystydzienski, Z.; Domanska‐Czyz, K.; Ostrowska, B.; Dabrowska‐Iwanicka, A.; Woroniecka, R.; Grygalewicz, B.; Osowiecki, M.; Jastrzebska, A.; Walewski, J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 333 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗